MPM
BMRN icon

MBB Public Markets’s BioMarin Pharmaceuticals BMRN Stock Holding History

MBB Public Markets’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-11,991
Closed -$987K – 583
2024
Q2 		$987K Buy
+11,991
New +$998K 0.02% 525

Other funds holding BMRN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
EIM
Elliott Investment Management West Palm Beach, Florida $20.1B AUM 60.76% 1-Year Est. Return

MBB Public Markets's BMRN Position: Q3 2024 in Review

MBB Public Markets sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2024, closing a stake of 11,991 shares — an estimated $987K sold.

MBB Public Markets first reported a position in BMRN in Q2 2024 and held it in 1 quarter. The position peaked at $987K in Q2 2024. 553 funds tracked by Wall St. Rank hold BMRN as of Q3 2024.

  • MBB Public Markets reported no remaining BioMarin Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • MBB Public Markets sold 11,991 BioMarin Pharmaceuticals shares in Q3 2024, an estimated $987K.
  • MBB Public Markets first reported a position in BioMarin Pharmaceuticals in Q2 2024 and held it in 1 quarter.
  • MBB Public Markets's BioMarin Pharmaceuticals position peaked at $987K in Q2 2024.
  • 553 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2024.

Based on MBB Public Markets's 13F filing for Q3 2024, filed 14 Nov 2024.